• FK866 (APO866) Workflows for NAMPT Research

  2026-09-19

  FK866 (APO866) enables controlled NAD depletion for mechanistic studies spanning hematologic cancer research and vascular-cell senescence. This practical guide connects dose design, metabolic readouts, mitochondrial assays, and troubleshooting to help researchers distinguish target-linked effects from nonspecific toxicity.

• Coronavirus Macrodomains Counter PARP Antiviral Activity

  2026-09-18

  Grunewald et al. showed that coronavirus macrodomains protect viral replication by opposing PARP-dependent ADP-ribosylation and its enhancement of interferon responses. Pharmacologic inhibition and targeted depletion identified PARP12 and PARP14 as important host restriction factors, providing a mechanistic framework for studying coronavirus–host interactions.

• Annexin V-Cy5 Apoptosis Kit: Lab Scenarios

  2026-09-17

  This scenario-driven guide explains how Annexin V-Cy5 Apoptosis Kit, SKU K2005, supports defensible Annexin V apoptosis detection in microscopy and flow cytometry workflows. It connects phosphatidylserine exposure with practical decisions in microglial stress, lysosomal dysfunction, protocol optimization, data interpretation, and product selection.

• Phenacetin Workflows for PK and Metabolism Studies

  2026-09-17

  Phenacetin provides a practical, research-only small-molecule comparator for absorption, metabolism, analytical recovery, and organoid workflows. This guide connects its solvent and stability profile with assay design while showing how to use it responsibly alongside, but not as a substitute for, emerging PDK4 inhibitor studies.

• Berberine hydrochloride Gut–Bone Workflows

  2026-09-17

  Berberine hydrochloride supports practical AMPK, microbiome, tuft-cell, barrier, and osteoimmune assay workflows. This guide translates a new gut–bone mechanism into controlled exposure, multi-omics, and troubleshooting strategies while distinguishing research evidence from clinical claims.

• Measuring Drug Response Beyond Cell Viability

  2026-09-16

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to clarify whether an anticancer treatment primarily slows proliferation, induces cell death, or does both. This framework emphasizes matched, time-resolved measurements and provides a practical basis for interpreting drug-response data in cancer research.

• How Cancer Drug Response Metrics Shape In Vitro Evidence

  2026-09-15

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent components of an in vitro cancer-drug response. Its central implication is practical: assay interpretation improves when researchers measure proliferation and death as separate, time-dependent outcomes rather than treating one viability value as a complete efficacy readout.

• MK-4827 (Niraparib) for PARP Research

  2026-09-15

  Build reproducible PARP-inhibition workflows with MK-4827 (Niraparib), from BRCA-mutant viability assays to DNA damage response profiling. The workflow also translates recent spliceosome findings in hepatocellular carcinoma into practical combination and biomarker experiments.

• Tivozanib (AV-951) Assay Design Guide

  2026-09-14

  This scenario-based guide explains how Tivozanib (AV-951), SKU A2251, can support reproducible cell viability, proliferation, and cytotoxicity workflows. It connects VEGFR signaling pathway inhibition with practical decisions about controls, formulation, exposure time, data interpretation, and supplier selection.

• Telatinib (BAY 57-9352) Assay Workflows

  2026-09-14

  Build mechanism-aware viability, phospho-signaling, invasion, and angiogenesis assays with Telatinib, a multi-receptor kinase inhibitor suited to pathway and phenotype studies. This workflow translates dual HER2–VEGFR2 findings in triple-negative breast cancer into practical controls, dosing strategies, and troubleshooting decisions.

• Doxorubicin Hydrochloride and Nucleolar Assays

  2026-09-13

  Doxorubicin hydrochloride is more than a cytotoxicity reagent: it can support integrated studies of DNA damage, metabolic stress, apoptosis, and nucleolar organization. This article connects Adriamycin HCl workflows with new insights into 28S rRNA-driven architecture while clearly separating established evidence from testable assay hypotheses.

• Caspase-3/7 Inhibitor I: A Practical Lab Guide

  2026-09-12

  This scenario-driven guide explains how Caspase-3/7 Inhibitor I (SKU A1925) can help researchers distinguish executioner-caspase-dependent apoptosis from nonspecific loss of viability. It covers selectivity, Jurkat-cell applications, handling, pathogen-model interpretation, and practical criteria for choosing a reliable reagent.

• Nelfinavir Mesylate: A Dual-Readout Research Guide

  2026-09-12

  Nelfinavir Mesylate is a well-characterized HIV-1 protease inhibitor with an emerging role in ferroptosis and proteostasis research. This guide presents an assay-centered framework for separating antiviral activity from DDI2–NFE2L1-dependent ferroptosis sensitization.

• Nintedanib: An ATRX-Aware Research Strategy

  2026-09-11

  Nintedanib (BIBF 1120) is more than a broad angiokinase inhibitor: it can serve as a genotype-aware probe in glioma and tumor-microenvironment studies. This article translates ATRX-dependent drug sensitivity into practical assay design, combination testing, and interpretation guidelines.

• HyperScribe™ Poly (A) Tailing Kit Workflow

  2026-09-11

  Build more consistent capped, polyadenylated RNA for transfection experiments and micro-injection by combining E. coli Poly (A) Polymerase with a controlled post-transcriptional workflow. This guide connects tail-length optimization with metabolic-expression assays inspired by the TCAIM–OGDH reference study, while clearly separating established product capabilities from practical recommendations.

551 records 4/37 page Previous Next 12345 下5页 Last page